^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Melanoma |
| Drug: | Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor) + S63845 (MCL1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
S63845, a selective inhibitor of MCL-1, cooperates with encorafenib in induction of apoptosis in BRAF V600E melanoma cells
Published date:
04/15/2021
Excerpt:
The aim of the present study was to systematically investigate apoptosis-related response of patient-derived BRAFV600E melanoma cell lines....It could be exploited to complement encorafenib activity by combining this BRAF inhibitor with S63845, a selective BH3 mimetic that targets MCL-1. This drug combination significantly increased the number of apoptotic cells...Our study indicates that combining encorafenib and S63845 can be considered as a putative anti-melanoma therapeutic strategy.
